TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03804515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-labeled poziotinib
Description: a single capsule containing 12 mg of 14C-labeled poziotinib (approximately 90 to 110 μCi) will be administered orally
Study: NCT02128165

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BMI more than 45 BMI
Description: Air filled gastric balloon (Heliosphere) those BMI above 45

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BMI less than 45 BMI
Description: Air filled gastric balloon (Heliosphere) those BMI below 45
Study: NCT00944281

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS-Zn5
Description: Daily consumption of 20 g LNS containing 5 mg of zinc and daily placebo supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LNS-Zn10
Description: Daily consumption of 20 g LNS containing 10 mg of zinc and daily placebo supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: LNS-Zn0
Description: 20 g of LNS containing 0 mg of zinc and a daily placebo supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Suppl-Zn5
Description: Daily 5 mg zinc supplement ant consumption of 20 g LNS containing 0 mg of zinc
Study: NCT01926522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological Rehabilitation
Description: The length of stride of reference used during the exercise is personalized and depends on the height of patients. Each patient carries out the feedback for 20 minutes with the aim of generating the most symmetric and regular gait.~Patients, with the dynamometer, work on strengthening of flexor and extensor muscles with ankle speeds at 90°/sec and 120°/sec. The strengthening technique was performed twice for 10 minutes each time with a 1 minute rest between sets.~The session ends with a 20-minute feedback on dynamic balance platform by carrying out exercises in which they need to reach randomly appearing targets. Subjects begin with 12 minutes the first 4 sessions, progress to 16 minutes the next 2 sessions, then 18' (2 sessions), and finally 20', if able, during the last 4 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Rehabilitation
Description: When needed, more than on e therapist are employed in the intervention for safety reasons.
Study: NCT00892190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib (SPRYCEL)
Description: DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all trans retinoic acid (VESANOID)
Description: 22.5mg/m2 every 12 hours
Study: NCT03485430

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tapering
Description: Tapering with follow up by nurse at weekly basis in beginning of tapering. Tapering in an outpatient setting. Follow-up to doctor after four months.
Study: NCT03672513

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Oral administration of 1 daily capsule containing lactose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Zinc Supplement
Description: Oral administration of 1 daily capsule containing 50 mg/day of Zn

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium supplement
Description: Oral administration of 1 daily capsule containing 500 mg/day of Magnesium
Study: NCT03075501

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paired
Description: Drug conditioning is assessed by pairing drug administration with a given context.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stimulant or sedative
Description: CS+ for paired, CS0 for unpaired

Intervention type: DRUG
Group type: OTHER
Intervention: Stimulant or sedative
Description: CS+ for paired, CS0 for unpaired

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: CS- for paired, CS0 for unpaired

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: CS- for paired, CS0 for unpaired
Study: NCT06217887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: loxenatide Group
Description: Loxenatide will be initiated and maintained at 0.2mg once weekly until the completion of the study. All patients will also continue on their existing dose and regimen of metformin throughout the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gliclazide Group
Description: Gliclazide will be initiated and maintained at 30mg/day every morning. If necessary, the dose can be increased to 120mg once daily. All patients will also continue on their existing dose and regimen of metformin throughout the study.
Study: NCT03941613

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SEEG guided RF-TC
Description: SEEG implantation after evaluation, record the interictal and ictal EEG, and perform RF-TC after the localization confirmation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior temporal lobectomy
Description: classical surgical treatment for mesial temporal lobe epilepsy, including the resection of neocortex for 5.5cm in non dominant hemisphere or 4.5cm in dominant hemisphere
Study: NCT04567693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early spaced-out appointments
Description: Newly-diagnosed PLWH currently attend health centers monthly for ART pick-up and quarterly for clinical visits. In the intervention arms, participants will attend health centers quarterly for ART pick-up and semi-annually for clinical visits.
Study: NCT06623175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture needles
Description: See arm description
Study: NCT04032106

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard information about HPV and HPV vaccine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive Outsmart HPV intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive Outsmart HPV intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message-Based Intervention
Description: Receive unidirectional text message vaccine reminders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Message-Based Intervention
Description: Receive interactive text message vaccine reminders
Study: NCT04483375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCTA01
Description: recombinant humanized anti-SARS-CoV-2 monoclonal antibody

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02039518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine 1000mg/m2，d1，d8，Q3W

Intervention type: OTHER
Group type: OTHER
Intervention: observation group
Description: observation group
Study: NCT04085172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine hydrochloride (TAK-503)
Description: Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablets once daily for 18 weeks in Part A or 52 weeks in Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine hydrochloride (TAK-503)
Description: Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg TAK-503 oral tablets once daily for 18 weeks in Part A or 52 weeks in Part B.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine hydrochloride
Description: Participants will receive Atomoxetine hydrochloride oral capsule once daily for 18 weeks in Part A.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants aged 6 to 12 years will receive a dose of 1 to 4 mg and aged 13 to 17 years will receive a dose of 5 to 7 mg placebo matched to TAK 503 oral tablets once daily for 18 weeks and placebo matched to atomoxetine hydrochloride oral capsules at once daily for 18 weeks in Part A.
Study: NCT04483817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Description: Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous tibial nerve stimulation
Description: Apply tibial nerve stimulation with surface electrodes in the treatment of overactive bladder.
Study: NCT02478034

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fludrocortisone
Description: effects of fludrocortisone on cognition compared to placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludrocortisone
Description: effects of fludrocortisone on cognition compared to placebo
Study: NCT01905553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184SS
Description: Disodium salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSP-004184SS
Description: Disodium salt
Study: NCT05685134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation
Description: Radiofrequency application via catheter to burn the electroanatomic substrate implicated in Brugada syndrome

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: Venous and epicardial punctions, catheter insertions, programmed electrical stimulation and electroanatomical mapping
Study: NCT03696108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 15 mg or 45 mg tablet administered orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant 15 mg or 45 mg tablet administered orally BID
Study: NCT00744315

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mini-thoracotomy for intramyocardial injection of VEGF165
Description: Patients with previous diagnosis of ischemic cardiopathy were included. The patient must accept and agree to be subject of clinical observation with current optimal treatment for at least 6 months. Following to that, subject undergoes intervention, in addition to consultation and assessments. Surgical technique -Ten injections VEGF165 will be made through a 25F butterfly needle in any ischemic territory where previously identified through scintigraphy. Dosis: 2.000 mg of VEGF165 in 5ml of saline solution. After the procedure, the patients will be kept in a recovery room for about 24hs and in the hospital until full clinical recovery.
Study: NCT03696108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to gefapixant 15 mg or 45 mg administered orally BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to gefapixant 15 mg or 45 mg administered orally BID
Study: NCT00723255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study: NCT02006797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reconciliation
Description: medication reconciliation at discharge and communication of this intervention to patient's community pharmacist
Study: NCT03946449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fazirsiran Injection (TAK-999, ARO-AAT)
Description: solution for subcutaneous (sc) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fazirsiran Injection (TAK-999, ARO-AAT)
Description: solution for subcutaneous (sc) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fazirsiran Injection (TAK-999, ARO-AAT)
Description: solution for subcutaneous (sc) injection
Study: NCT01687465

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Argon laser trabeculoplasty
Description: With Argon laser trabeculoplasty (ALT), thermal energy is used directed towards the Trabecular Meshwork (the site of aqueous drainage from the eye),which causes focal scarring of trabecular meshwork, thus enable fluid drainage more effectively. However, this procedure may not be repeatable since it causes too much damage to the trabecular meshwork.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Argon laser trabeculoplasty
Description: With Argon laser trabeculoplasty (ALT), thermal energy is used directed towards the Trabecular Meshwork (the site of aqueous drainage from the eye),which causes focal scarring of trabecular meshwork, thus enable fluid drainage more effectively. However, this procedure may not be repeatable since it causes too much damage to the trabecular meshwork.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty
Description: Selective laser trabeculoplasty is a relatively newer technology that uses a Nd:YAG laser to target specific cells within the trabecular meshwork. SLT does not cause coagulative damage to the trabecular meshwork, and thus has the advantage of being repeatable.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty
Description: Selective laser trabeculoplasty is a relatively newer technology that uses a Nd:YAG laser to target specific cells within the trabecular meshwork. SLT does not cause coagulative damage to the trabecular meshwork, and thus has the advantage of being repeatable.
Study: NCT01077609

Intervention type: DRUG
Intervention: Intermittent, sub-chronic and chronic Flixonase use
Description: Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.

Intervention type: DRUG
Intervention: Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase
Description: Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
Study: NCT02032862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sage extract, 3400 mg , DER 1:17
Study: NCT03992573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CGF application
Description: CGF application into post-operative soft tissue and bone defects
Study: NCT01245543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC480IV
Description: AC480IV will be administered as an infusion using a dose escalation design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered intravenously, initially as monotherapy and subsequently in combination with docetaxel immediately following AC480IV administration.
Study: NCT04654754

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: high-flow high humidity oxygen device with tracheostomy adapter
Description: This device can provide heat and humidified gas for spontaneous breathing patients with tracheostomy at a high gas flow rate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow high humidity oxygen device with tracheostomy adapter
Description: This device can provide heat and humidified gas for spontaneous breathing patients with tracheostomy at a high gas flow rate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow high humidity oxygen device with tracheostomy adapter
Description: This device can provide heat and humidified gas for spontaneous breathing patients with tracheostomy at a high gas flow rate.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high-flow high humidity oxygen device with tracheostomy adapter
Description: This device can provide heat and humidified gas for spontaneous breathing patients with tracheostomy at a high gas flow rate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-flow high humidity oxygen device with tracheostomy adapter
Description: This device can provide heat and humidified gas for spontaneous breathing patients with tracheostomy at a high gas flow rate.
Study: NCT02784613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ospemifene
Description: FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia
Study: NCT03886779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromfenac
Description: 0.7 MG/ML \[Prolensa\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nepafenac
Description: 3 MG/ML \[Ilevro\]
Study: NCT05033730

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow Controlled Ventilation
Description: Mechanically ventilated using Flow Controlled Ventilation (FCV)
Study: NCT00638443

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin
Description: Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
Study: NCT00634985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eletriptan
Description: 40 mg oral tablet for migraine attack; additional 40 mg oral tablet \>2 hours from first dose if migraine reoccurred within 24 hours of achieving response
Study: NCT01821430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Titration of intervention will begin with 50mg PO BID x 2 days, then 100mg PO BID x 2 days, then 150mg PO BID X 2 days, then on day 7 full dose of Pregabalin 400mg PO QD for six weeks
Study: NCT01821430

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will follow the same titration as the pregabalin group
Study: NCT02384967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: to assess efficacy of a reduced dose strategy of darunavir to 400 mg/d in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mg/d and two nucleoside reverse transcriptase inhibitors (NRTI), to maintain the viral load lower than 50 copies / mL at 48 weeks of treatment.
Study: NCT00749385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN 400
Description: A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC naproxen plus EC esomeprazole
Description: Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC naproxen
Description: Enteric-coated naproxen tablet (500mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC esomeprazole
Description: Enteric-coated esomeprazole capsule (20mg)
Study: NCT00818103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: Atorvastatin 40mg p.o. qn for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: β-interferon
Description: β-interferon 50ug i.m. qod for 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO
Description: EPO 10000U i.h. bid for 5 days
Study: NCT02292810

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle exercise
Description: For inspiratory muscle exercise patients will breathe with a high load of 60% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) until task failure. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by continuous glucose monitoring system.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inspiratory muscle exercise placebo
Description: For inspiratory muscle exercise patients will breathe with a very low load of 2% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) for 10 minute. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by using the continuous glucose monitoring system.
Study: NCT00808301

Intervention type: OTHER
Group type: OTHER
Intervention: Gluten-free products
Description: Gluten-free bakery products containing oatmeal.
Study: NCT00638443

Intervention type: DRUG
Group type: OTHER
Intervention: Diphenhydramine
Description: diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.

Intervention type: DRUG
Group type: OTHER
Intervention: Diphenhydramine
Description: diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
Study: NCT03492398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HY209
Description: 6 subjects will be assigned to drug (HY209) and 2 subjects will be assigned to placebo.